Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

Jonathan M. Meyer, Vicki G. Davis, Joseph Patrick McEvoy, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Gail L. Daumit, John Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial. Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months. Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p = 0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean + 54.7 mg/dl, median + 26 mg/dl) and olanzapine (mean + 23.4 mg/dl, median + 26.5 mg/dl), while ziprasidone was neutral (mean + 0.0 mg/dl, median + 8 mg/dl), and decreases were seen with risperidone (mean - 18.4 mg/dl, median - 6.5 mg/dl) and perphenazine (mean - 1.3 mg/dl, median - 22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p = 0.002) and a trend for perphenazine vs. quetiapine (p = 0.006). Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalSchizophrenia Research
Volume103
Issue number1-3
DOIs
StatePublished - Aug 1 2008

Fingerprint

Antipsychotic Agents
Schizophrenia
Triglycerides
olanzapine
Perphenazine
Risperidone
Serum
Fasting
Consensus
Quetiapine Fumarate

Keywords

  • Antipsychotic
  • Cardiovascular risk
  • Lipids
  • Nonfasting
  • Schizophrenia
  • Triglycerides

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Meyer, J. M., Davis, V. G., McEvoy, J. P., Goff, D. C., Nasrallah, H. A., Davis, S. M., ... Lieberman, J. A. (2008). Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research, 103(1-3), 104-109. https://doi.org/10.1016/j.schres.2008.04.023

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. / Meyer, Jonathan M.; Davis, Vicki G.; McEvoy, Joseph Patrick; Goff, Donald C.; Nasrallah, Henry A.; Davis, Sonia M.; Daumit, Gail L.; Hsiao, John; Swartz, Marvin S.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 103, No. 1-3, 01.08.2008, p. 104-109.

Research output: Contribution to journalArticle

Meyer, JM, Davis, VG, McEvoy, JP, Goff, DC, Nasrallah, HA, Davis, SM, Daumit, GL, Hsiao, J, Swartz, MS, Stroup, TS & Lieberman, JA 2008, 'Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1', Schizophrenia Research, vol. 103, no. 1-3, pp. 104-109. https://doi.org/10.1016/j.schres.2008.04.023
Meyer, Jonathan M. ; Davis, Vicki G. ; McEvoy, Joseph Patrick ; Goff, Donald C. ; Nasrallah, Henry A. ; Davis, Sonia M. ; Daumit, Gail L. ; Hsiao, John ; Swartz, Marvin S. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. In: Schizophrenia Research. 2008 ; Vol. 103, No. 1-3. pp. 104-109.
@article{985a023bdce84c2cbc771295e2601fda,
title = "Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1",
abstract = "Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial. Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months. Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p = 0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean + 54.7 mg/dl, median + 26 mg/dl) and olanzapine (mean + 23.4 mg/dl, median + 26.5 mg/dl), while ziprasidone was neutral (mean + 0.0 mg/dl, median + 8 mg/dl), and decreases were seen with risperidone (mean - 18.4 mg/dl, median - 6.5 mg/dl) and perphenazine (mean - 1.3 mg/dl, median - 22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p = 0.002) and a trend for perphenazine vs. quetiapine (p = 0.006). Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.",
keywords = "Antipsychotic, Cardiovascular risk, Lipids, Nonfasting, Schizophrenia, Triglycerides",
author = "Meyer, {Jonathan M.} and Davis, {Vicki G.} and McEvoy, {Joseph Patrick} and Goff, {Donald C.} and Nasrallah, {Henry A.} and Davis, {Sonia M.} and Daumit, {Gail L.} and John Hsiao and Swartz, {Marvin S.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1016/j.schres.2008.04.023",
language = "English (US)",
volume = "103",
pages = "104--109",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

AU - Meyer, Jonathan M.

AU - Davis, Vicki G.

AU - McEvoy, Joseph Patrick

AU - Goff, Donald C.

AU - Nasrallah, Henry A.

AU - Davis, Sonia M.

AU - Daumit, Gail L.

AU - Hsiao, John

AU - Swartz, Marvin S.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial. Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months. Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p = 0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean + 54.7 mg/dl, median + 26 mg/dl) and olanzapine (mean + 23.4 mg/dl, median + 26.5 mg/dl), while ziprasidone was neutral (mean + 0.0 mg/dl, median + 8 mg/dl), and decreases were seen with risperidone (mean - 18.4 mg/dl, median - 6.5 mg/dl) and perphenazine (mean - 1.3 mg/dl, median - 22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p = 0.002) and a trend for perphenazine vs. quetiapine (p = 0.006). Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.

AB - Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial. Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months. Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p = 0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean + 54.7 mg/dl, median + 26 mg/dl) and olanzapine (mean + 23.4 mg/dl, median + 26.5 mg/dl), while ziprasidone was neutral (mean + 0.0 mg/dl, median + 8 mg/dl), and decreases were seen with risperidone (mean - 18.4 mg/dl, median - 6.5 mg/dl) and perphenazine (mean - 1.3 mg/dl, median - 22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p = 0.002) and a trend for perphenazine vs. quetiapine (p = 0.006). Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.

KW - Antipsychotic

KW - Cardiovascular risk

KW - Lipids

KW - Nonfasting

KW - Schizophrenia

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=47249104183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249104183&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.04.023

DO - 10.1016/j.schres.2008.04.023

M3 - Article

C2 - 18534821

AN - SCOPUS:47249104183

VL - 103

SP - 104

EP - 109

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -